LaZure Treats First Human Patient

Issaquah, WA

LaZure Scientific, Inc. announced today that the first human patient was treated using LaZure’s Low Dose Alternating Current (LDAC) prostate cancer treatment device on Friday September 14, 2012.  The treatment was performed at the Medulla Clinic in the Republic of Georgia as part of LaZure’s first-in-man Study of Feasibility of Low-Dose Alternating Electric Current (LDAC) as a Treatment for Low-Risk Prostate Cancer.

The procedure was completed successfully and the clinicians were pleased with how the LDAC system performed.  The patient was released from the clinic on Monday.  The patient will be followed for 6-weeks for adverse events at which point a prostatectomy will be performed and histological analysis of the tissue will be completed to evaluate effectiveness.

“The treatment of the first human patient marks the most significant milestone in our company’s history thus far.”  Remarked LaZure CEO Charles Hill.  “It is our belief that LDAC technology has the potential to change the way prostate cancer is treated throughout the world.”

A second patient is scheduled for treatment in early October as part of the study.

LaZure Scientific, Inc. is a development stage medical device company pioneering LDAC Technology, a proprietary, breakthrough cancer treatment method that employs low dose, alternating electric current to preferentially destroy cancer cells. LaZure’s first treatment device using LDAC is designed to provide effective, whole-gland treatment of early stage prostate cancer without creating serious side effects such as impotence and incontinence. This device is currently for investigational use only and has not been cleared for use in the U.S. by the FDA. For more information about LaZure and LDAC Technology, contact LaZure Scientific, Inc. at 1-855-552-9873.

Sorry, comments are closed for this post.